Access Denied

Modern Alzheimer's management requires an "MRI metronome". For anti-amyloid therapies, rigid adherence to routine MRI schedules is essential to detect dangerous amyloid-related imaging abnormalities (ARIA). Read our arti...

Talent shortages are emerging as a critical challenge for Asia-Pacific biotech companies. A recent ICON survey found that biotech professionals in APAC were nearly three times more likely than their global peers to repor...

Latest issue now available. Join thousands of subscribers who have discovered the convenience of our free monthly publication, by signing up today. https://ow.ly/hTYQ50Zu7sT Compiled and collated by ICON’s Regulatory I...

Accelerated approval is not a shortcut – it is a strategic decision that demands robust planning. In this latest Drug & Device World article, ICON’s Elizabeth Madichie and Jack Martin highlight why surrogate endpoints m...

ICON reports second quarter 2026 results. Quarter two revenue of $2,063.5 million, an increase of 1.4% on quarter one 2026. Net business wins in the quarter of $3,120 million; a net book-to-bill of 1.51. Read more https:...

With more than 70 COPD therapies in development, differentiation has never been more important. As development programmes become increasingly targeted, sponsors must integrate biomarker-informed strategies, patient-focu...

As more innovative therapies emerge from the APAC region, sponsors seeking global approval face increasingly complex regulatory decisions. Our latest article in PharmaTimes Magazine examines key considerations for navig...

Heart failure affects millions of people worldwide and can significantly impact quality of life. Research into new treatment approaches remains critical to improving outcomes and expanding options for patients living wit...

ICON today announced a multi-year collaboration with Anthropic to bring Claude’s AI capabilities across the clinical trial lifecycle. The collaboration further advances ICON’s digital innovation and AI strategy, and buil...

When Alyssa Gilliam joined ICON as a Clinical Trial Assistant in 1998, she expected it to be a temporary step. It became the start of a career shaped by new challenges, strong relationships and a willingness to keep lear...

Global clinical development is entering a more connected, data-driven era. While the FDA is piloting real-time clinical trials, other regulatory bodies are advancing AI and digital strategies in different ways, creating...

AI can improve speed and scale but trust still requires people. ICON’s Mia Malmenäs emphasizes that human expertise remains essential for interpreting incomplete evidence, evaluating AI outputs, applying regulatory and ...